2-N-(4-fluorophenyl)-6-N-[(2-fluoropyridin-4-yl)methyl]-4-N-phenyl-1,3,5-triazine-2,4,6-triamine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-N-(4-fluorophenyl)-6-N-[(2-fluoropyridin-4-yl)methyl]-4-N-phenyl-1,3,5-triazine-2,4,6-triamine
• 化学式: C₂₁H₁₇F₂N₇
• 分子量: 405.4
• InChiKey: OSBKFUBDPQDRKX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  87.6
• 氢给体数：
  3
• 氢受体数：
  9

文献信息

• NOVEL PHARMACEUTICAL COMPOSITION FOR TREATMENT OF SCHIZOPHRENIA
  申请人：TAKAHASHI Shinji

  公开号：US20100256152A1

  公开（公告）日：2010-10-07

  The present invention is useful for providing an excellent pharmaceutical composition for prevention and/or treatment of schizophrenia, containing a BEC1 potassium channel inhibitor or a pharmaceutically acceptable salt thereof as an active ingredient, and is particularly useful for providing a pharmaceutical composition for prevention and/or treatment of the positive symptoms, negative symptoms, cognitive impairments and the like of schizophrenia.

  本发明有助于提供一种优秀的药物组合，用于预防和/或治疗精神分裂症，其包含BEC1钾通道抑制剂或其药学上可接受的盐作为活性成分，特别适用于提供一种预防和/或治疗精神分裂症的阳性症状、阴性症状、认知障碍等的药物组合。
• NOVEL PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER
  申请人：Takahashi Shinji

  公开号：US20120088772A1

  公开（公告）日：2012-04-12

  The present invention is to provide a therapeutic agent for attention deficit/hyperactivity disorder having a novel mechanism of action which is different from conventional psychostimulants. The present invention is useful for providing an excellent pharmaceutical composition for prevention and/or treatment of attention deficit/hyperactivity disorder, comprising a BEC1 potassium channel inhibitor or a pharmaceutically acceptable salt thereof as an active ingredient, and is particularly useful for providing a pharmaceutical composition for prevention and/or treatment of inattention, impulsivity, and hyperactivity in attention deficit/hyperactivity disorder.

  本发明旨在提供一种治疗注意力缺陷/多动障碍的治疗剂，其具有与传统的精神刺激剂不同的新型作用机制。本发明有助于提供一种优良的药物组合物，作为预防和/或治疗注意力缺陷/多动障碍的药物组合物，包括BEC1钾通道抑制剂或其药学上可接受的盐作为活性成分，并且特别适用于提供一种用于预防和/或治疗注意力缺陷/多动障碍中的注意力不集中、冲动和多动的药物组合物。
• 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE
  申请人：Astellas Pharma Inc.

  公开号：EP1479397B1

  公开（公告）日：2011-06-08
• US7375222B2
  申请人：——

  公开号：US7375222B2

  公开（公告）日：2008-05-20